Why the study?
Does targeted disruption of the IGFBP-2 gene alter organ sizes and body growth in mice?
Does targeted disruption of the IGFBP-2 gene alter organ sizes and body growth in mice?
IGFBP-2 plays a critical role in modulating spleen and liver size, and its absence leads to compensatory up-regulation of multiple other IGFBPs in mice.
Answers are grounded in this paper and cite their sources.
IGFBP-2 deletion effects in male mice should not yet inform practice; hypothesis-generating for compensatory IGFBP roles in human organ growth.
Insulin-like growth factor binding protein 2 (IGFBP-2) is one member of the family of IGF binding proteins believed to have both endocrine functions elicited by modulating serum IGF half-life and transport as well as autocrine/paracrine functions that result from blocking or enhancing the availability of IGFs to bind cell surface receptors. To clarify the in vivo role of IGFBP-2, we have used gene targeting to introduce a null IGFBP-2 allele into the mouse genome. Animals homozygous for the altered allele are viable and fertile, contain no IGFBP-2 mRNA, and have no detectable IGFBP-2 in the adult circulation. Heterozygous and homozygous animals showed no significant differences in prenatal or postnatal body growth. Analyses of organ weights in adult males, however, revealed that spleen weight was reduced and liver weight was increased in the absence of IGFBP-2. In addition, ligand blot analyses of sera from adult IGFBP-2 null males showed that IGFBP-1, IGFBP-3, and IGFBP-4 levels were increased relative to wild-type mice. These results demonstrate that up-regulation of multiple IGFBPs accompanies the absence of IGFBP-2 and that IGFBP-2 has a critical role, either directly or indirectly, in modulating spleen and liver size.
No takes yet. Share an insight, caveat, or question.
Teresa L. Wood (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: